Role of V-ATPases in solid tumors: Importance of the subunit C (review)

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1513-1520

  Pérez Sayáns, Mario ^a   García García, Abel ^a   Reboiras López, María Dolores ^a   Gándara Vila, Pilar ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Oral squamous cell carcinoma; V ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; ADENOSINE TRIPHOSPHATASE V; ADENOSINE TRIPHOSPHATASE V SUBUNIT C; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

CANCER CONTROL; CARCINOGENESIS; CELL PH; CRYSTALLOGRAPHY; CYTOSOLIC FRACTION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LYSOSOME MEMBRANE; MEMBRANE STABILIZATION; METASTASIS POTENTIAL; MICROENVIRONMENT; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

HUMANS; NEOPLASMS; PROTEIN SUBUNITS; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 67649438642     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000280     Document Type: Review

References (76)

1. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ and Hendrix MJ: Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176-186, 1996.
2. Raghunand N, Mahoney B, van Sluis R, Baggett B and Gillies RJ: Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 3: 227-235, 2001.
3. Morita T, Nagaki T, Fukuda I and Okumura K: Clastogenicity of low pH to various cultured mammalian cells. Mutat Res 268: 297-305, 1992.
4. De Milito A and Fais S: Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother 6: 1049-1054, 2005.
5. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, et al: Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 29: 541-549, 2003.
6. Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H and Ishiguchi H: Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 13: 237-243, 2002.
7. Gillies RJ, Raghunand N, Karczmar GS and Bhujwalla ZM: MRI of the tumor microenvironment. J Magn Reson Imaging 16: 430-450, 2002.
8. + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 14: 2185-2197, 2000.
9. Juel C: Lactate-proton cotransport in skeletal muscle. Physiol Rev 77: 321-358, 1997.
10. Raghunand N and Gillies RJ: pH and drug resistance in tumors. Drug Resist Updat 3: 39-47, 2000.
11. + exchanger in metastasis. Nat Rev Cancer 5: 786-795, 2005.
12. +-ATPase in cancer biology. Cell Biochem Biophys 40: 185-206, 2004.
13. Hagag N, Lacal JC, Graber M, Aaronson S and Viola MV: Microinjection of ras p21 induces a rapid rise in intracellular pH. Mol Cell Biol 7: 1984-1988, 1987.
14. Ober SS and Pardee AB: Intracellular pH is increased after transformation of Chinese hamster embryo fibroblasts. Proc Natl Acad Sci USA 84: 2766-2770, 1987.
15. Reshkin SJ, Bellizzi A, Albarani V, Guerra L, Tommasino M and Paradiso A: Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J Biol Chem 275: 5361-5369, 2000.
16. + antiporter in normal and transformed human lymphocytes and fibroblasts. Am J Physiol 267: C745-C752, 1994.
17. Doppler W, Jaggi R and Groner B: Induction of v-mos and activated Ha-ras oncogene expression in quiescent NIH 3T3 cells causes intracellular alkalinisation and cell-cycle progression. Gene 54: 147-153, 1987.
18. Pouyssegur J, Franchi A and Pages G: pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp 240: 186-196, 2001.
19. Newell K, Franchi A, Pouyssegur J and Tannock I: Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 90: 1127-1131, 1993.
20. Yamagata M, Hasuda K, Stamato T and Tannock IF: The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 77: 1726-1731, 1998.
21. De Milito A and Fais S: Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 1: 779-786, 2005.
22. Nelson N and Harvey WR: Vacuolar and plasma membrane proton-qdenosinetriphosphatases. Physiol Rev 79: 361-385, 1999.
23. Saroussi S and Nelson N: Vacuolar H(+)-ATPase-an enzyme for all seasons Pflugers Arch 457: 581-587, 2009.
24. Martinez-Zaguilan R, Lynch RM, Martinez GM and Gillies RJ: Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol Cell Physiol 265: C1015-C1029, 1993.
25. McLean LA, Roscoe J, Jorgensen NK, Gorin FA and Cala PM: Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol 278: C676-C688, 2000.
26. Perona R and Serrano R: Increased pH and tumorigenicity of fibroblasts expressing a yeast proton pump. Nature 334: 438-440, 1988.
27. +-ATPases in angiogenesis, diabetes and cancer. J Bioenerg Biomembr 39: 427-433, 2007.
28. Montcourrier P, Silver I, Farnoud R, Bird I and Rochefort H: Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 15: 382-392, 1997.
29. Parkins CS, Stratford MR, Dennis MF, Stubbs M and Chaplin DJ: The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer 75: 319-323, 1997.
30. +-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286: C1443-C1452, 2004.
31. Otero-Rey EM, Somoza-Martin M, Barros-Angueira F and Garcia-Garcia A: Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene. Oral Oncol 44: 193-199, 2008.
32. +-V-ATPase to the actin cytoskeleton. J Biol Chem 278: 18499-18505, 2003.
33. Izumi H, Ise T, Murakami T, Torigoe T, Ishiguchi H and Uramoto H: Structural and functional characterization of two human V-ATPase subunit gene promoters. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1628: 97-104, 2003.
34. + exchanger in cancer angiogenesis and antiangiogenesis. Br J Cancer 89: 1395-1399, 2003.
35. +-ATPases at the plasma membrane regulate pH and cell migration in microvascular endothelial cells. Am J Physiol Heart Circ Physiol 291: H1147-H1157, 2006.
36. +-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 57: 1037-1046, 1999.
37. Nishi T and Forgac M: The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat Rev Mol Cell Biol 3: 94-103, 2002.
38. Nelson N, Perzov N, Cohen A, Hagai K, Padler V and Nelson H: The cellular biology of proton-motive force generation by V-ATPases. J Exp Biol 203: 89-95, 2000.
39. +-ATPases as a new strategy against cancer. Cancer Res 67: 10627-10630, 2007.
40. +-ATPases by fusidic acid and suramin. FEBS Lett 234: 383-386, 1988.
41. Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JW and Hayakawa Y: Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-ATPases. J Pharmacol Exp Ther 297: 114-120, 2001.
42. Nishihara T, Akifusa S, Koseki T, Kato S, Muro M and Hanada N: Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death. Biochem Biophys Res Commun 212: 255-262, 1995.
43. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M and Marino ML: Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 67: 5408-5417, 2007.
44. Bahar G, Feinmesser R, Shpitzer T, Popovtzer A and Nagler RM: Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 109: 54-59, 2007.
45. Yoshimoto Y and Imoto M: Induction of EGF-dependent apoptosis by vacuolar-type H(+)-ATPase inhibitors in A431 cells overexpressing the EGF receptor. Exp Cell Res 279: 118-127, 2002.
46. Germanov E, Berman JN and Guernsey DL: Current and future approaches for the therapeutic targeting of metastasis (review). Int J Mol Med 18: 1025-1036, 2006.
47. Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, et al: The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 65: 6843-6849, 2005.
48. Ohta T, Numata M, Yagishita H, Futagami F, Tsukioka Y and Kitagawa H: Expression of 16 kDa proteolipid of vacuolar-type H(+)-ATPase in human pancreatic cancer. Br J Cancer 73: 1511-1517, 1996.
49. Goldstein DJ, Finbow ME, Andresson T, McLean P, Smith K and Bubb V: Bovine papillomavirus E5 oncoprotein binds to the 16K component of vacuolar H(+)-ATPases. Nature 352: 347-349, 1991.
50. Andresson T, Sparkowski J, Goldstein DJ and Schlegel R: Vacuolar H(+)-ATPase mutants transform cells and define a binding site for the papillomavirus E5 oncoprotein. J Biol Chem 270: 6830-6837, 1995.
51. Schapiro F, Sparkowski J, Adduci A, Suprynowicz F, Schlegel R and Grinstein S: Golgi alkalinization by the papillomavirus E5 oncoprotein. J Cell Biol 148: 305-315, 2000.
52. Huss M, Ingenhorst G, Konig S, Gassel M, Drose S, Zeeck A, et al: Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. J Biol Chem 277: 40544-40548, 2002.
53. Fernandes F, Loura LM, Fedorov A, Dixon N, Kee TP and Prieto M: Binding assays of inhibitors towards selected V-ATPase domains. Biochim Biophys Acta 1758: 1777-1786, 2006.
54. Menche D, Hassfeld J, Sasse F, Huss M and Wieczorek H: Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor. Bioorg Med Chem Lett 17: 1732-1735, 2007.
55. +-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther 318: 939-946, 2006.
56. Niikura K: Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis. Cancer Chemother Pharmacol 60: 555-562, 2007.
57. Smith AN, Borthwick KJ and Karet FE: Molecular cloning and characterization of novel tissue-specific isoforms of the human vacuolar H(+)-ATPase C, G and d subunits, and their evaluation in autosomal recessive distal renal tubular acidosis. Gene 297: 169-177, 2002.
58. Svergun DI, Konrad S, Huss M, Koch MH, Wieczorek H and Altendorf K: Quaternary structure of V1 and F1 ATPase: significance of structural homologies and diversities. Biochemistry 37: 17659-17663, 1998.
59. Armbruster A, Svergun DI, Coskun U, Juliano S, Bailer SM and Gruber G: Structural analysis of the stalk subunit Vma5p of the yeast V-ATPase in solution. FEBS Lett 570: 119-125, 2004.
60. Zhang Z, Inoue T, Forgac M and Wilkens S: Localization of subunit C (Vma5p) in the yeast vacuolar ATPase by immuno electron microscopy. FEBS Lett 580: 2006-2010, 2006.
61. Chaban YL, Juliano S, Boekema EJ and Gruber G: Interaction between subunit C (Vma5p) of the yeast vacuolar ATPase and the stalk of the C-depleted V(1) ATPase from Manduca sexta midgut. Biochim Biophys Acta 1708: 196-200, 2005.
62. Drory O, Frolow F and Nelson N: Crystal structure of yeast V-ATPase subunit C reveals its stator function. EMBO Rep 5: 1148-1152, 2004.
63. Inoue T and Forgac M: Cysteine-mediated cross-linking indicates that subunit C of the V-ATPase is in close proximity to subunits E and G of the V1 domain and subunit a of the V0 domain. J Biol Chem 280: 27896-27903, 2005.
64. Forgac M: Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 8: 917-929, 2007.
65. Peng S, Stone D and Xie X: Reconstitution of recombinant 40-kDa subunit of the clathrin-coated vesicle H(+)-ATPase. J Biol Chem 268: 23519-23523, 1993.
66. Gruber G: Structural features and nucleotide-binding capability of the C subunit are integral to the regulation of the eukaryotic V1Vo ATPases. Biochem Soc Trans 33: 883-885, 2005.
67. Armbruster A, Hohn C, Hermesdorf A, Schumacher K, Borsch M and Gruber G: Evidence for major structural changes in subunit C of the vacuolar ATPase due to nucleotide binding. FEBS Lett 579: 1961-1967, 2005.
68. Puopolo K, Sczekan M, Magner R and Forgac M: The 40-kDa subunit enhances but is not required for activity of the coated vesicle proton pump. J Biol Chem 267: 5171-5176, 1992.
69. Beltran C, Kopecky J, Pan YC, Nelson H and Nelson N: Cloning and mutational analysis of the gene encoding subunit C of yeast vacuolar H(+)-ATPase. J Biol Chem 267: 774-779, 1992.
70. Voss M, Vitavska O, Walz B, Wieczorek H and Baumann O: Stimulus-induced phosphorylation of vacuolar H(+)-ATPase by protein kinase A. J Biol Chem 282: 33735-33742, 2007.
71. Smardon AM and Kane PM: RAVE is essential for the efficient assembly of the C subunit with the vacuolar H(+)-ATPase. J Biol Chem 282: 26185-26194, 2007.
72. +-ATPase complexes resulting from overproduction of Vma5p and Vma13p. J Biol Chem 277: 2716-2724, 2002.
73. Ma L and Center MS: The gene encoding vacuolar H(+)-ATPase subunit C is overexpressed in multidrug-resistant HL60 cells. Biochem Biophys Res Commun 182: 675-681, 1992.
74. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S and Nakagawa M: Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 93: 869-874, 2001.
75. Bowman BJ and Bowman EJ: Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J Biol Chem 6: 3965-3972, 2002.
76. Martinez Muñoz GA and Kane P: Vacuolar and plasma membrane proton pumps collaborate to achieve cytosolic pH homeostasis in yeast. J Biol Chem 29: 20309-20319, 2008.